Inside The Pet Industry

The Transformative Trends Shaping Animal Health and Veterinary Care in 2024 and Beyond

The animal health industry has been on an incredible journey, with innovation, humanization, and sustainability driving its evolution. As pet owners worldwide increasingly view their furry friends as family members, their expectations for veterinary care are transforming, and companies like Zoetis and IDEXX Laboratories are at the forefront of this shift. Let’s dig in.

1. The Humanization of Pets: A Multi-Billion Dollar Phenomenon

Let’s start with a trend that has reshaped everything from pet food to diagnostics: the humanization of pets. An astounding 95% of pet owners in the U.S. now consider their pets as part of the family, according to the American Pet Products Association. This emotional connection is driving a surge in demand for advanced, human-grade veterinary care.

What does this mean for the industry?

For Zoetis, it means remarkable growth in its Companion Animal Segment, which saw a 15% operational increase in Q3 2024. Products like Librela and Solensia, designed for managing osteoarthritis pain in pets, have been standout performers, with Solensia’s 97% global revenue growth showcasing the growing willingness of pet owners to invest in cutting-edge treatments for their aging companions.

Meanwhile, IDEXX Laboratories recorded a 7% organic growth in its Companion Animal Group Diagnostics Recurring Revenues, reflecting how diagnostics are becoming a top priority for proactive pet care. Aging pets especially require high-quality care, and owners are not holding back when it comes to spending on their beloved animals.

The numbers don’t lie: the global companion animal healthcare market is projected to reach $34 billion by 2027, growing at an impressive 9.5% CAGR. The strongest drivers? Solutions for chronic pain, advanced diagnostics, and cancer detection—Zoetis and IDEXX are leading the way in all these categories.

2. Rising Demand for Preventive and Chronic Care

Here’s an eye-opener: 40% of dogs worldwide suffer from osteoarthritis, yet a staggering 17 million dogs in the U.S. remain untreated. This gap represents both a challenge and an opportunity for the veterinary industry.

Preventive and chronic care solutions are stepping up. IDEXX’s premium diagnostics instruments, such as Catalyst and Hematology platforms, are seeing double-digit growth in placements, signaling a shift toward early disease detection. Their VetLab consumable revenues grew 11% organically, driven by the adoption of diagnostics tools that help detect chronic conditions like arthritis and cancer early.

On the treatment side, Zoetis continues to shine with its Dermatology Franchise, which grew 16% operationally to reach $449 million in Q3 2024 revenues. Its blockbuster products, Apoquel and Cytopoint, cater to chronic dermatological issues, which are becoming more common as pets age.

Why is this shift important? Chronic disease diagnostics and treatments are expanding at a 7%-8% CAGR globally, and preventive care alone accounts for 32% of veterinary clinic revenues in the U.S. By addressing unmet needs like untreated osteoarthritis or undiagnosed cancers, companies are unlocking significant growth opportunities.

3. Diagnostics: From Niche to Necessity

Diagnostics are no longer just a complementary service in veterinary care—they’re a necessity. IDEXX has taken the lead, achieving 6% organic growth in its CAG Diagnostics Recurring Revenues in Q3 2024. What’s striking is that diagnostic visits in the U.S. grew, even as overall clinical visits declined by 2.1% due to economic headwinds.

Global demand is also heating up. IDEXX’s Reference Lab Revenues grew 2% organically, bolstered by robust retention rates of over 97%. On a larger scale, the veterinary diagnostics market is projected to grow at a 9.6% CAGR, reaching $8.9 billion by 2027.

Zoetis, for its part, continues to see strong uptake in therapeutic veterinary visits. Since its U.S. launch, Librela has brought treatment to 500,000 new osteoarthritis patients, proving the potential of diagnostics-driven care pathways.

The takeaway? Diagnostics are becoming a cornerstone of modern veterinary practice, creating win-win scenarios for pets, pet owners, and the companies providing these solutions.

4. Retail Distribution and E-Commerce: Changing the Game

How do you get more pet owners to comply with treatment plans? Meet them where they shop. Zoetis has capitalized on this idea, with 20% of Simparica Trio’s U.S. sales now coming from retail channels. The product achieved a staggering 27% operational growth globally in Q3, driven by its convenience-focused distribution strategy.

E-commerce is a rising star, with the online sale of pet care products projected to grow at a 9% CAGR through 2030. This channel has proven particularly effective for preventive treatments like Simparica Trio, which is now prescribed to 35% of U.S. puppies.

5. Emerging Markets: The Next Frontier

Emerging markets are playing an increasingly vital role in global veterinary growth. IDEXX’s international revenues grew 10% organically, with China and Europe leading the charge. Zoetis, meanwhile, recorded 13% international operational growth, fueled by demand for livestock vaccines and companion animal products in developing regions.

A standout performer? Simparica Trio. In markets like Brazil and Eastern Europe, the product saw a 22% operational sales increase, underlining the massive potential for growth in these regions. By 2030, emerging markets are expected to drive 40% of global veterinary market growth, making this a key area of focus for industry leaders.

6. Sustainability and Livestock Health

In the livestock segment, Zoetis is pivoting toward sustainable, high-growth areas like vaccines and genetics, evidenced by the recent sale of its medicated feed additive (MFA) portfolio for $400 million. These solutions not only ensure healthier animals but also align with climate-conscious farming practices.

With the livestock health market expected to grow at an 8.3% CAGR to reach $40 billion by 2026, innovation in sustainability-focused solutions—like vaccine-based disease prevention—will remain critical.

7. Aging Pet Populations and Specialized Care

Here’s a striking statistic: 40% of pets over the age of seven require chronic disease management, and owners are stepping up to meet these needs. Zoetis’s Librela and Solensia, which generated $192 million in their first year, are prime examples of specialized care solutions gaining traction.

Looking forward, IDEXX is betting big on its IDEXX Cancer Dx Panel, targeting the $1.1 billion canine oncology diagnostics market in 2025. Aging-related veterinary services are also expected to grow at an 8.5% CAGR, reflecting the increasing lifespans of pets.

The Big Picture: Collaboration and Innovation Drive Success

From preventive care to diagnostics, Zoetis and IDEXX are driving transformative change in the animal health industry. Their complementary strategies—Zoetis’s focus on therapeutic breakthroughs and IDEXX’s leadership in diagnostics and software solutions—are reshaping the sector and meeting the needs of an evolving market.

As we look ahead, one thing is clear: the companies that prioritize innovation, global reach, and sustainability will remain at the forefront of this exciting industry. Whether it’s meeting the needs of aging pets, tapping into emerging markets, or championing sustainable livestock health, the future of animal health has never looked brighter.

So, what’s next for the industry? Perhaps the better question is: how can you, as an investor or pet owner, help shape it?

P.S: If you found this article insightful, please take a moment to like or repost it. Doing so not only helps spread valuable knowledge but also signals to me that you appreciate this kind of content. It’s a simple way for you to influence the type of articles I produce—more business breakdowns, industry insights, and actionable analyses tailored to what you find most useful.

Here’s the deal: your engagement matters. By liking this post, you’re not just supporting my work; you’re actively shaping the kind of content you’ll see in the future. I do the hard work of gathering data, analyzing trends, and breaking it all down into digestible insights for you. All you need to do is read, learn, and build your mental database of how businesses truly work.

Now, a quick note for those who’ve found this content invaluable: I offer a premium newsletter subscription that delivers daily in-depth insights like this one straight to your inbox. The price of the subscription is currently $237/year, but this offer is only available until Sunday, February 2nd, at 11:59 PM California time, and there are less than 10 spots remaining at this price. After these spots are gone, or the deadline passes, the price will increase progressively, eventually reaching $500/year.

Why act now? By subscribing today, you lock in the lowest price forever. It’s like buying knowledge at a discount—a knowledge base that compounds over time and helps you make smarter decisions, avoid costly mistakes, and understand the core mechanics of industries like no one else.

Think about it: it’s less than the cost of a coffee a day. And unlike coffee, the knowledge you gain here will stay with you, building exponentially over time. Your payment details will be securely managed by Stripe, a platform trusted to handle billions of dollars in transactions.

But remember, spots are disappearing fast. The initial 10 spots are almost gone, and they may not last until the deadline. If you’re serious about improving your understanding of business and investing in your future, now’s the time to act.

Thank you for being part of this community. Let’s keep learning, growing, and unlocking the potential of every insight—together.